Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29433
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorHANS-FILHO, Gunter-
dc.contributor.authorAOKI, Valeria-
dc.contributor.authorBITTNER, Nelise Ritter Hans-
dc.contributor.authorBITTNER, Guilherme Canho-
dc.date.accessioned2018-11-21T17:01:01Z-
dc.date.available2018-11-21T17:01:01Z-
dc.date.issued2018-
dc.identifier.citationANAIS BRASILEIROS DE DERMATOLOGIA, v.93, n.5, p.638-650, 2018-
dc.identifier.issn0365-0596-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/29433-
dc.description.abstractFogo selvagem or endemic pemphigus foliaceus is an autoimmune acantholytic anti-cadherin bullous disease that primarily affects seborrheic areas, which might disseminate. Brazil has the world's largest number of patients, mainly in the Central-West region, but the disease has also been reported in other South American countries. It affects young people and adults who have been exposed to rural areas, with occurrence of familial cases. Anti-desmoglein-1 autoantibodies are directed against desmosomal structures, with loss of adhesion of the upper layers of the epidermis, causing superficial blisters. The etiology is multifactorial and includes genetic, immune, and environmental factors, highlighting hematophagous insect bites; drug-related factors are occasionally involved. Flaccid blisters readily rupture to yield erosive-crusty lesions that sometimes resemble seborrheic dermatitis, actinic keratosis, and chronic cutaneous lupus erythematosus. The clinical presentation varies from localized to disseminated lesions. Clinical suspicion should be confirmed with histopathological and immunofluorescence tests, among others. The progression is usually chronic, and therapy varies according to dinical presentation, but generally requires systemic corticosteroid therapy associated with adjuvant immunosuppressive treatment to decrease the adverse effects of corticosteroids. Once the disease is under control, many patients remain stable on low-dose medication, and a significant proportion achieve remission.-
dc.language.isoeng-
dc.publisherSOC BRASILEIRA DERMATOLOGIA-
dc.relation.ispartofAnais Brasileiros de Dermatologia-
dc.rightsopenAccess-
dc.subjectAutoimmunity-
dc.subjectDesmoglein 1-
dc.subjectSkin diseases-
dc.subjectvesiculobullous-
dc.subjectPemphigus-
dc.subject.otherdrug-induced pemphigus-
dc.subject.otherbrazilian pemphigus-
dc.subject.otherdesmoglein 1-
dc.subject.otherclinical-features-
dc.subject.otherpassive transfer-
dc.subject.otherautoantibodies-
dc.subject.otherdisease-
dc.subject.otherantibodies-
dc.subject.othervulgaris-
dc.subject.otherprevalence-
dc.titleFogo selvagem: endemic pemphigus foliaceus-
dc.typearticle-
dc.rights.holderCopyright SOC BRASILEIRA DERMATOLOGIA-
dc.identifier.doi10.1590/abd1806-4841.20188235-
dc.identifier.pmid30156612
dc.subject.wosDermatology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalHANS-FILHO, Gunter:Univ Fed Mato Grosso do Sul, Fac Med, Dept Dermatol, Campo Grande, MS, Brazil; Univ Fed Mato Grosso do Sul, Hosp Maria Aparecida Pedrossian, Dermatol Serv, Campo Grande, MS, Brazil-
hcfmusp.author.externalBITTNER, Nelise Ritter Hans:Univ Fed Mato Grosso do Sul, Hosp Maria Aparecida Pedrossian, Dermatol Serv, Campo Grande, MS, Brazil-
hcfmusp.author.externalBITTNER, Guilherme Canho:Univ Fed Mato Grosso do Sul, Hosp Maria Aparecida Pedrossian, Dermatol Serv, Campo Grande, MS, Brazil-
hcfmusp.description.beginpage638-
hcfmusp.description.endpage650-
hcfmusp.description.issue5-
hcfmusp.description.volume93-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000442757000001-
hcfmusp.origem.id2-s2.0-85052502526-
hcfmusp.origem.idSCIELO:S0365-05962018000500638
hcfmusp.publisher.cityRIO DE JANEIRO RJ-
hcfmusp.publisher.countryBRAZIL-
hcfmusp.relation.referenceAMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B-
hcfmusp.relation.referenceAMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968-
hcfmusp.relation.referenceAmagai M, 2012, DERMATOLOGY, V1, P461-
hcfmusp.relation.referenceANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001-
hcfmusp.relation.referenceAoki V, 2004, J INVEST DERM SYMP P, V9, P34, DOI 10.1111/j.1087-0024.2004.00833.x-
hcfmusp.relation.referenceAoki V, 2015, J DERMATOL, V42, P18, DOI 10.1111/1346-8138.12675-
hcfmusp.relation.referenceArakawa M, 2009, J DERMATOL SCI, V53, P228, DOI 10.1016/j.jdermsci.2008.09.008-
hcfmusp.relation.referenceAvalos-Diaz E, 2000, J AM ACAD DERMATOL, V43, P1130, DOI 10.1067/mjd.2000.110400-
hcfmusp.relation.referenceBASTUJIGARIN S, 1995, J INVEST DERMATOL, V104, P302, DOI 10.1111/1523-1747.ep12612836-
hcfmusp.relation.referenceBEUTNER EH, 1964, P SOC EXP BIOL MED, V117, P505-
hcfmusp.relation.referenceBEUTNER EH, 1968, P SOC EXP BIOL MED, V127, P81-
hcfmusp.relation.referenceBrenner S, 1998, CLIN DERMATOL, V16, P393, DOI 10.1016/S0738-081X(98)00010-8-
hcfmusp.relation.referenceBrenner S, 2011, CLIN DERMATOL, V29, P455, DOI 10.1016/j.clindermatol.2011.01.016-
hcfmusp.relation.referenceCAMPOS JA, 1942, PENFIGO FOLIACEO FOG-
hcfmusp.relation.referenceCastro S, 1937, REV TERAPEUT, P80-
hcfmusp.relation.referenceChriguer RS, 2012, J CLIN IMMUNOL, V32, P786, DOI 10.1007/s10875-012-9679-y-
hcfmusp.relation.referenceCivatte A., 1943, ANN DERM SYPH PARIS, V3, P1-
hcfmusp.relation.referenceCOUNTER CE, 1959, ARCH DERMATOL, V80, P391, DOI 10.1001/archderm.1959.01560220001001-
hcfmusp.relation.referenceCulton DA, 2008, J AUTOIMMUN, V31, P311, DOI 10.1016/j.jaut.2008.08.003-
hcfmusp.relation.referenceDaniel BS, 2012, CLIN DERMATOL, V30, P108, DOI 10.1016/j.clindermatol.2011.03.017-
hcfmusp.relation.referenceDeSauvages FB., 1968, NOSOLOGIA METHODICA, p[1, 431]-
hcfmusp.relation.referenceDi Zenzo G, 2012, J INVEST DERMATOL, V132, P2499, DOI 10.1038/jid.2012.369-
hcfmusp.relation.referenceDIAZ LA, 1989, J AM ACAD DERMATOL, V20, P657, DOI 10.1016/S0190-9622(89)70079-7-
hcfmusp.relation.referenceDIAZ LA, 1989, J INVEST DERMATOL, V92, P4, DOI 10.1111/1523-1747.ep13070394-
hcfmusp.relation.referenceDiaz LA, 2004, J INVEST DERMATOL, V123, P1045, DOI 10.1111/j.0022-202X.2004.23438.x-
hcfmusp.relation.referenceDiaz LA, 2008, J INVEST DERMATOL, V128, P667, DOI 10.1038/si.jid.5701121-
hcfmusp.relation.referenceEvangelista F, 2018, J AUTOIMMUN, V89, P171, DOI 10.1016/j.jaut.2017.12.017-
hcfmusp.relation.referenceFlores G, 2012, J INVEST DERMATOL, V132, P2573, DOI 10.1038/jid.2012.232-
hcfmusp.relation.referenceGrando SA, 2012, AUTOIMMUNITY, V45, P7, DOI 10.3109/08916934.2011.606444-
hcfmusp.relation.referenceGualberto L., 1912, AN 7 C BRAS MED CIR, V4, P429-
hcfmusp.relation.referenceHans G, 1996, J INVEST DERMATOL, V107, P68, DOI 10.1111/1523-1747.ep12298213-
hcfmusp.relation.referenceHans G, 1999, CLIN DERMATOL, V17, P225, DOI 10.1016/S0738-081X(99)00014-0-
hcfmusp.relation.referenceHans-Filho G, 2017, TROPICAL DERMATOLOGY, P427-
hcfmusp.relation.referenceHertl M, 2017, IN MAN PEMPH VULG PE-
hcfmusp.relation.referenceHilario-Vargas J, 2006, J INVEST DERMATOL, V126, P2044, DOI 10.1038/sj.jid.5700388-
hcfmusp.relation.referenceHolubar K., 1990, MANAGEMENT BLISTERIN, P1-
hcfmusp.relation.referenceJames KA, 2011, DERMATOL CLIN, V29, P405, DOI 10.1016/j.det.2011.03.012-
hcfmusp.relation.referenceJuneja Manish, 2008, J Oral Sci, V50, P213, DOI 10.2334/josnusd.50.213-
hcfmusp.relation.referenceKarnofsky DA, 1949, EVALUATION CHEMOTHER, P196-
hcfmusp.relation.referenceKasperkiewicz M, 2012, CLIN DERMATOL, V30, P84, DOI 10.1016/j.clindermatol.2011.03.014-
hcfmusp.relation.referenceKing D F, 1983, Clin Dermatol, V1, P6-
hcfmusp.relation.referenceLEVER WF, 1953, MEDICINE, V32, P1-
hcfmusp.relation.referenceLi N, 2003, J EXP MED, V197, P1501, DOI 10.1084/jem.20022031-
hcfmusp.relation.referenceLopez-Robles E, 2001, INT J DERMATOL, V40, P185, DOI 10.1046/j.1365-4362.2001.01083.x-
hcfmusp.relation.referenceMahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252-
hcfmusp.relation.referenceMARSDEN RA, 1976, BRIT MED J, V2, P1423, DOI 10.1136/bmj.2.6049.1423-
hcfmusp.relation.referenceMcBride D., 1777, METHODICAL INTRO THE-
hcfmusp.relation.referenceMoraes ME, 1997, TISSUE ANTIGENS, V49, P35, DOI 10.1111/j.1399-0039.1997.tb02707.x-
hcfmusp.relation.referenceMutasim DE, 2004, J AM ACAD DERMATOL, V51, P859, DOI 10.1016/j.jaad.204.02.013-
hcfmusp.relation.referenceNikolsky PV, 1986, MED OBOESRENYE, V2, P126-
hcfmusp.relation.referencePayne AS, 2012, FITZPATRICKS DERMATO, V1, P586-
hcfmusp.relation.referencePiovezan BZ, 2013, HUM IMMUNOL, V74, P1134, DOI 10.1016/j.humimm.2013.06.008-
hcfmusp.relation.referenceQaqish BF, 2009, J INVEST DERMATOL, V129, P110, DOI 10.1038/jid.2008.189-
hcfmusp.relation.referenceQian Y, 2012, J IMMUNOL, V189, P1535, DOI 10.4049/jimmunol.1200842-
hcfmusp.relation.referenceRivitti EA, 2006, TROPICAL DERMATOLOGY, P421-
hcfmusp.relation.referenceROBLEDO MA, 1988, BRIT J DERMATOL, V118, P737, DOI 10.1111/j.1365-2133.1988.tb02590.x-
hcfmusp.relation.referenceRocha-Rodrigues DB, 2003, CLIN DIAGN LAB IMMUN, V10, P741, DOI 10.1128/CDLI.10.5741-743.2003-
hcfmusp.relation.referenceROSCOE JT, 1985, J INVEST DERMATOL, V85, P538, DOI 10.1111/1523-1747.ep12277362-
hcfmusp.relation.referenceRudolph JL, 2005, LANCET, P36661-
hcfmusp.relation.referenceSchmidt E, 2010, ARCH DERMATOL RES, V302, P241, DOI 10.1007/s00403-009-1024-9-
hcfmusp.relation.referenceSebaratnam DF, 2011, DERMATOL CLIN, V29, P515, DOI 10.1016/j.det.2011.03.015-
hcfmusp.relation.referenceSilva JR, 1948, ANN BRAS DERMATOL SI, V23, P273-
hcfmusp.relation.referenceSitaru C, 2005, EXP DERMATOL, V14, P861, DOI 10.1111/j.1600-0625.2005.00367.x-
hcfmusp.relation.referenceTimoteo RP, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00978-
hcfmusp.relation.referencevan der Wier G, 2012, BRIT J DERMATOL, V167, P1265, DOI 10.1111/j.1365-2133.2012.11173.x-
hcfmusp.relation.referenceVieira JP., 1937, CONTRIBUICAO ESTUDO-
hcfmusp.relation.referenceWarren SJP, 2000, NEW ENGL J MED, V343, P23, DOI 10.1056/NEJM200007063430104-
hcfmusp.relation.referenceWarren SJP, 2003, J INVEST DERMATOL, V120, P104, DOI 10.1046/j.1523-1747.2003.12017.x-
hcfmusp.relation.referenceWaschke J, 2008, HISTOCHEM CELL BIOL, V130, P21, DOI 10.1007/s00418-008-0420-0-
hcfmusp.relation.referenceYoshida K, 2017, J DERMATOL SCI, V85, P197, DOI 10.1016/j.jdermsci.2016.12.010-
dc.description.indexMEDLINE-
dc.identifier.eissn1806-4841-
hcfmusp.citation.scopus10-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDT
Departamento de Dermatologia - FM/MDT

Artigos e Materiais de Revistas Científicas - LIM/56
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências


Files in This Item:
File Description SizeFormat 
art_HANS-FILHO_Fogo_selvagem_endemic_pemphigus_foliaceus_2018.PDFpublishedVersion (English)3.8 MBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.